Literature DB >> 20507178

Structural analysis of botulinum neurotoxin type G receptor binding .

John Schmitt1, Andrew Karalewitz, Desirée A Benefield, Darren J Mushrush, Rory N Pruitt, Benjamin W Spiller, Joseph T Barbieri, D Borden Lacy.   

Abstract

Botulinum neurotoxin (BoNT) binds peripheral neurons at the neuromuscular junction through a dual-receptor mechanism that includes interactions with ganglioside and protein receptors. The receptor identities vary depending on BoNT serotype (A-G). BoNT/B and BoNT/G bind the luminal domains of synaptotagmin I and II, homologous synaptic vesicle proteins. We observe conditions under which BoNT/B binds both Syt isoforms, but BoNT/G binds only SytI. Both serotypes bind ganglioside G(T1b). The BoNT/G receptor-binding domain crystal structure provides a context for examining these binding interactions and a platform for understanding the physiological relevance of different Syt receptor isoforms in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507178      PMCID: PMC2894633          DOI: 10.1021/bi100412v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.

Authors:  S Swaminathan; S Eswaramoorthy
Journal:  Nat Struct Biol       Date:  2000-08

2.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

Review 3.  The synaptic vesicle cycle.

Authors:  Thomas C Sudhof
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

4.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

5.  A molecular viewer for the analysis of TLS rigid-body motion in macromolecules.

Authors:  Jay Painter; Ethan A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-03-24

6.  Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.

Authors:  Jay Painter; Ethan A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-03-18

7.  Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.

Authors:  Rongsheng Jin; Andreas Rummel; Thomas Binz; Axel T Brunger
Journal:  Nature       Date:  2006-12-13       Impact factor: 49.962

8.  Structural basis of cell surface receptor recognition by botulinum neurotoxin B.

Authors:  Qing Chai; Joseph W Arndt; Min Dong; William H Tepp; Eric A Johnson; Edwin R Chapman; Raymond C Stevens
Journal:  Nature       Date:  2006-12-13       Impact factor: 49.962

9.  Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.

Authors:  Andreas Rummel; Tino Karnath; Tina Henke; Hans Bigalke; Thomas Binz
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

10.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

View more
  16 in total

1.  Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.

Authors:  Keiji Nakamura; Tomoko Kohda; Yuto Shibata; Kentaro Tsukamoto; Hideyuki Arimitsu; Mitsunori Hayashi; Masafumi Mukamoto; Nobuyuki Sasakawa; Shunji Kozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.

Authors:  Lisheng Peng; Ronnie P-A Berntsson; William H Tepp; Rose M Pitkin; Eric A Johnson; Pål Stenmark; Min Dong
Journal:  J Cell Sci       Date:  2012-03-27       Impact factor: 5.285

Review 3.  Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin.

Authors:  Kwok-Ho Lam; Guorui Yao; Rongsheng Jin
Journal:  Prog Biophys Mol Biol       Date:  2015-02-19       Impact factor: 3.667

4.  Structural analysis of the receptor binding domain of botulinum neurotoxin serotype D.

Authors:  Yanfeng Zhang; Garry W Buchko; Ling Qin; Howard Robinson; Susan M Varnum
Journal:  Biochem Biophys Res Commun       Date:  2010-09-19       Impact factor: 3.575

5.  Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II.

Authors:  Ronnie Per-Arne Berntsson; Lisheng Peng; Linda Marie Svensson; Min Dong; Pål Stenmark
Journal:  Structure       Date:  2013-08-08       Impact factor: 5.006

6.  Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly.

Authors:  Shihu Sun; Swetha Suresh; Huisheng Liu; William H Tepp; Eric A Johnson; J Michael Edwardson; Edwin R Chapman
Journal:  Cell Host Microbe       Date:  2011-09-15       Impact factor: 21.023

7.  Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Authors:  Lisheng Peng; William H Tepp; Eric A Johnson; Min Dong
Journal:  PLoS Pathog       Date:  2011-03-31       Impact factor: 6.823

8.  Beltless translocation domain of botulinum neurotoxin A embodies a minimum ion-conductive channel.

Authors:  Audrey Fischer; Shilpa Sambashivan; Axel T Brunger; Mauricio Montal
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

Review 9.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

Review 10.  Emerging opportunities for serotypes of botulinum neurotoxins.

Authors:  Zhongxing Peng Chen; J Glenn Morris; Ramon L Rodriguez; Aparna Wagle Shukla; John Tapia-Núñez; Michael S Okun
Journal:  Toxins (Basel)       Date:  2012-11-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.